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based gene delivery vectors hold a great potential for clinical ap-
plications because of their presumed non-immunogenicity and
capacity to induce immune tolerance to the transgene products
in humans. However, the clinical use of SV40 vectors has been
hampered by the lack of a packaging cell line that produces repli-
cation-competent (RC) free SV40 particles in the vector produc-
tion process. To solve this problem, we have adapted the current
SV40 vector genome used for the production of vector particles
and generated a novel Vero-based packaging cell line named
SuperVero that exclusively expresses the SV40 large T antigen.
SuperVero cells produce similar numbers of SV40 vector parti-
cles compared to the currently used packaging cell lines, albeit
in the absence of contaminating RC SV40 particles. Our unique
SV40 vector platformnamed SVacpaves theway to clinically test
a whole new generation of SV40-based therapeutics for a broad
range of important diseases.Received 8 May 2017; accepted 30 June 2017;
http://dx.doi.org/10.1016/j.omtm.2017.06.007.
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After small molecules and therapeutic proteins, gene therapy will be
the next wave of medicines potentially capable of curing today’s major
diseases. Key to the success of gene therapy will be the safe and effi-
cient delivery of the therapeutic genes into cells of the affected tissue
or organ target cells of a patient’s body. Viruses evolve to efficiently
transfer and express their genes into host cells. This ability renders
them ideally suited for use as gene delivery vectors. Among the viral
vector systems currently used for gene therapy, lentiviral (LV) and
adeno-associated viral (AAV) vectors are the most popular because
they transduce a wide variety of tissues and mediate long-term
expression when administered to animals.1–3 For both vectors it
has been shown that such replication-defective (RD) viral
vectors are non-immunogenic or tolerogenic in hosts that are naive
to the cognate virus.4–8 After successful preclinical and clinical
trials, the first LV and AAV vector-based therapeutics have now
reached the market.9 However, both LV and AAV vector systems
have shortcomings that limit their application.
LV vectors integrate randomly in the host genome, and thus increase
the risk of insertional mutagenesis.10 Moreover, LV vector particles124 Molecular Therapy: Methods & Clinical Development Vol. 6 Septem
This is an open access article under the CC BY-NC-ND license (httpare highly instable, rapidly degraded when administered in vivo,
and the development of stable packaging cell lines has remained chal-
lenging.11 For these reasons, LV vectors are mainly used for the
ex vivo transduction of leukocytes and/or their progenitors to treat
blood-related genetic disorders, lysosomal storage diseases, or cancer.
AAV vectors are mainly used for in vivo gene therapies. However, the
majority of the human population encountered wild-type AAV
together with its helper virus (adenovirus, causing the common
cold) and developed a strong humoral and cellular immune memory
for the AAV capsid proteins. Clinical studies using recombinant AAV
vectors revealed that administration of vector particles elicits innate
and adaptive immune responses against the viral and transgene-en-
coded proteins in the vast majority of treated patients, leading to
decreasing expression levels of the therapeutic transgenes over time
and elimination of the transduced cells from the body, compromising
re-administration of the vector. The few treated patients who showed
long-term transgene expression most likely have never been infected
with AAV, and thus were immunologically naive to the RD vector
used in the study. For these reasons, the efficacy of AAV vector-based
in vivo gene therapies is limited.12,13
RD simian virus 40 (SV40) vectors could be an attractive alternative
to AAV vectors for clinical gene therapy.14 SV40 is a polyomavirus
with icosahedral capsids of 45 nm in size containing a 5.25 kb-long
circular double-stranded DNA. The virus strictly replicates in its nat-
ural host, macaques, where it causes chronic asymptomatic infections.
SV40 particles enter infected cells via the caveolar-endosomal route,
but in contrast with other viruses are able to avoid the lysosomal
degradation, thereby evading exposure to the host immune sys-
tem.15–21 RD SV40 vectors have been generated by deleting the coding
region of the two early non-structural proteins named large T antigen
(LTag) and small T antigen (STag), giving 2.7 kb of space for cloning
the transgene encoding the therapeutic protein or RNA. SV40 vectorsber 2017 ª 2017 The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Schematic Representation of the SV40 Vector Destination
Plasmid pSVac
The Gateway gene cassette comprising the ccdB and the chloramphenicol resis-
tance (CmR) genes present in pSVac is substituted by the transgene using Gateway
recombination yielding an SV40 vector expression plasmid.
www.moleculartherapy.orgtransduce a wide range of cell types in vivo, and their therapeutic
potential has been demonstrated in animal models of human dis-
ease.22–26 Because humans can be considered naive to SV40,27,28 it
is expected that RD SV40 vectors are non-immunogenic or tolero-
genic when applied in clinical settings. The non-immunogenicity in
humans and capacity to induce immune tolerance to transgene pro-
teins render SV40 vectors highly attractive for use in gene replace-
ment and immunotherapies.
However, the translation of SV40 vectors to the clinic has been
hampered by the lack of a packaging cell line that does not accumulate
detectable amounts of replication-competent (RC) SV40 particles
during vector production.29–32 To date, two cell lines have been
mainly used for the production of SV40 vectors: COS-1 and COS-7.
COS cell lines were generated by transformation of monkey CV1 cells
with SV40 DNA.29 Passaging of SV40 vectors in COS cells, however,
results in the appearance of wild-type SV40 particles. This most likely
occurs by sequence homology-dependent recombination between the
chromosomally inserted SV40-specific DNA sequences and episom-
ally replicating vector-specific DNA sequences.33
Other cell lines that express the SV40 T antigens in trans are COT18
and CMT4. Both CV1-derived cell lines were generated using SV40
DNA in which the T antigens were expressed under transcriptional
control of the mousemetallothionein promoter. Because the complete
early region of the SV40 genomic DNA is present in the chromosomal
DNA, the ability that RC virus contaminants emerge during the vec-
tor production process has remained. Moreover, the vector yields of
both packaging cell lines are not increased compared with those of
COS cells.33–35
Polyomavirus-based virus-like particle (VLP) vector systems have
been developed to prevent the occurrence of RC virus particles inMolecular Ththe vector preparations. In vitro-generated VLPs consisting of circu-
lar double-stranded DNA encapsidated with polyomavirus VP1 lack
VP2 and VP3 in the capsids and histones covering the encapsidated
DNA molecules. Although these particles display a higher packaging
capacity, the absence of VP2/VP3 in the VLPs has a negative impact
on their entry in the nucleus.36
In order to overcome the generation of wild-type virus contaminants,
we optimized the SV40 vector genome used to initiate the production
of vector particles and generated a safe and efficient Vero-based SV40
vector packaging cell line named SuperVero. The SuperVero cells
solely express the viral LTag and accumulate vector particles at
high titers, comparable with those obtained in the conventional pack-
aging cell lines COS-1 and COS-7. Because RD SV40 vectors are safe,
highly efficient for gene delivery, and non-immunogenic/tolerogenic
in humans, our improved SV40 vector platform named SVac holds
promising qualities for developing effective treatments for the major
diseases of our time.37
RESULTS
Construction of SV40 Vector Destination pSVac and Derivative
Vector Expression Plasmids
In order to improve the efficacy and versatility of the SV40 vector sys-
tem, we modified vector plasmid pSL-PL38 in a series of steps yielding
SV40 destination plasmid pSVac (Figure 1) that is used to initiate the
production of recombinant SV40 particles. The low copy number
bacterial backbone of pSL-PL (pBR322) was replaced with a high
copy number backbone (pBluescript SK). The residual 30-terminal
LTag coding sequences present in pSL-PL were removed, and a
Gateway gene cassette derived from pEF5/FRT/V5-DEST was intro-
duced in the early region of the SV40 vector DNA, providing a versa-
tile method to introduce transgenes encoding therapeutic proteins or
RNAs into the vector destination plasmid by LR clonase-mediated
recombination between pSVac DNA and that of an entry plasmid
harboring a transgene resulting in vector expression plasmids. The
bovine growth hormone (BGH) polyadenylation (pA) signal origi-
nating from pEF5/FRT/V5-DEST was cloned downstream of the
Gateway cassette to facilitate transient expression studies by transfect-
ing target cells with DNA from vector expression plasmids. Unique
AscI and SpeI restriction sites were introduced between the SV40 early
promoter and the Gateway cassette to facilitate the introduction of tis-
sue-specific promoters. We generated a series of SV40 expression
plasmids containing different transgenes by Gateway recombination.
The resulting expression plasmids encode the jellyfish green fluores-
cent protein (pSVGFP), the human activated blood clotting factor VII
(pSVFVIIa), and a short hairpin RNA specific for the firefly luciferase
(pSVshLuc).
For the generation of SV40 vector particles, the prokaryotic backbone
of pSVac needs to be removed from the SV40 vector sequences. For
this purpose, NotI restriction sites and loxP recombination sites
were introduced between the Gateway cassette and BGH pA signal
and between the SV40 pA signal and the pBluescript SK bacterial
backbone. Circular vector DNA used as starting material for theerapy: Methods & Clinical Development Vol. 6 September 2017 125
Figure 2. Vero Cells Stably Transfected with pHY359 Support the
Production of SVLuc Vector Particles
(A) Schematic representation of the expression plasmids pHY338 and pHY359.
Plasmid pHY338 contains the SV40 genomic T antigen sequence encoding both
LTag and STag. Plasmid pHY359 contains the LTag cDNA sequence encoding
LTag only. In both plasmids, transgene expression is driven by the EF-1a promoter.
Both plasmids contain the puromycin resistance (PuroR) gene under transcriptional
control of the CMVie promoter and BGH pA signal. (B) Ratio between the number of
SVLuc particles produced in Vero cells transfected with pHY338 and pHY359
plasmid DNA and those produced in COS-1 cells transduced with SVLuc particles.
(C) Luminescence of COS-1 cells transduced with SVLuc particles produced in
transfected Vero or COS-1 cells. (D) Luminescence of COS-1 cells transduced with
SVLuc particles produced in stably transfected Vero cell clones. COS-1 cells were
used as positive control.
Molecular Therapy: Methods & Clinical Developmentproduction of SV40 vector particles in packaging cells was generated
by digesting a vector expression plasmid with NotI followed by re-
circularization of the vector DNA using T4 DNA ligase. Alternatively,
circular vector DNA can be generated by homologous recombination
at the loxP sites using Cre recombinase.
Generation of a New SV40 Vector Packaging Cell Line
The SV40 T antigens are required for virus DNA replication and
expression of the late gene encoding the viral capsid proteins. In order
to verify whether the LTag by itself is sufficient for the generation of126 Molecular Therapy: Methods & Clinical Development Vol. 6 SeptemSV40 vector particles, we generated the expression plasmids pHY338
and pHY359 as described under Materials and Methods. Expression
plasmid pHY338 encodes both STag and LTag; plasmid pHY359
exclusively encodes LTag (Figure 2A). Vero cells were selected as
acceptor cells for both expression plasmids because these cells are
permissive for SV40 and because Vero constitutes an accepted cell
culture platform for vaccine production.39 Vero cells grown in
serum-free cell culture medium were transfected with either
pHY338 or pHY359 DNA, and cells were cultured for 1 month in
serum-free culture medium supplemented with puromycin. Puro-
mycin-resistant cell clones were subsequently transduced with SVLuc
particles produced in COS-1 cells31 at an MOI of 100. As a positive
control, COS-1 cells were transduced with SVLuc particles at the
same MOI. Three days after transduction, the amount of SVLuc
particles present in the culture medium of the transduced cells was
determined by quantitative real-time PCR. The qPCR assay has
been developed in such a way that only packaged vector genomes
are measured (Figure 2B). Both the pHY338 and pHY359-transfected
Vero cells produced vector particles at approximately 30% of the
amount of vector particles produced in COS-1 cells. To verify that
the vector particles produced in the transfected Vero cells are
biologically active, we subsequently used the culture media from
the SVLuc-transduced Vero and COS-1 cells for transducing fresh
COS-1 cells. Three days after transduction, crude cell lysates were
prepared and the luciferase activity was determined in these lysates
by luminescence. Figure 2C shows that the transfected Vero cells
produced vector particles that induced luciferase expression when
transferred to COS-1 cells. These experiments demonstrated that
the presence of SV40 LTag in Vero cells is sufficient for producing
SV40 vector particles.
In order to generate a new Vero-based packaging cell line for the pro-
duction of SV40 vector particles, we cultured cells transfected with
pHY359 DNA in the presence of puromycin for 1 month. Individual
puromycin-resistant cell colonies were picked and sub-cultured in cul-
ture medium with puromycin. More than 100 puromycin-resistant
colonies were obtained and subsequently tested for their capacity to
produce SV40 vector particles using the same assay as described above.
One cell colony produced comparable amounts of SVLuc particles to
COS-1 cells (Figure 2D). Subsequently, six subclones of this cell colony
were generated by limited dilution of the puromycin-resistant cells and
tested for their capacity to produce vector particles using the same
assay. The cell clone that produced the largest amount of vector parti-
cles, denoted SuperVero, was expanded in serum-free culture medium
without puromycin and used for generating a research cell bank of 50
vials that is stored at 150C. For all further studies, vials of the
research cell bank were thawed and the cells were cultured and
expanded in serum-free glutamine-supplemented OptiPRO medium.
Molecular Analysis of the SuperVero Packaging Cell Line
In order to confirm the presence of a functional LTag-encoding gene in
the chromosomal DNA of SuperVero cells and to investigate whether
the cells harbor contaminating viruses, the transcriptome of SuperVero
cells was analyzed by Massive Parallel Sequencing (MP-Seq).40 Moreber 2017
Table 1. Comparison of the cDNA Reads of SuperVero and Vero Cells to a Viral Sequence Database
Original Accession
No. Identified











Total No. of Reads
Mapped to Refseqa
NC_001669.1 202b 238b 0 0 NC_001669 simian virus 40, complete genome
AC146999.1 63 97 0 14 NC_006273 human herpesvirus 5
EU410304.1 23 21 13 3 NC_006998 vaccinia virus GLV-1h68
X03922.1 17 97 0 14 NC_006273 human herpesvirus 5
HM143845.1 12 0 6 0 M11841 simian retrovirus 1
U85506.1 9 18 10 14 U85505 simian endogenous retrovirus
Z54175.1 7 10 5 5 NC_001461 bovine viral diarrhea virus 1
AF104029.1 6 1 6 0 NC_002032 bovine viral diarrhea virus 2
FM212572.1 4 5,330 1 2,926 AB047240 human endogenous retrovirus
JN134185.1 3 87 7 18 JN134185 simian endogenous retrovirus SRVcae
AF290913.1 1 0 0 1 U13766 murine leukemia virus
M15805.1 1 64 0 21 M15805 feline sarcoma virus
aA single read may map to multiple positions of the reference sequence and each mapping is counted independently.
b202 cDNA reads mapped to the LTag gene present in the genomic DNA of the cells.
www.moleculartherapy.orgthan 1.6 million different cDNA sequences from SuperVero poly-A-
positive RNAs were generated. In parallel, more than 800,000 different
cDNA sequences were generated from poly-A-positive RNAs isolated
from reference cell line Vero ATCC CCL-81.
Among the SuperVero cDNA sequences, 202 cDNA reads mapped to
the LTag gene present in the genomic DNA of the cells (see Table 1).
SV40 cDNA sequences specific for other parts of the SV40 genome
were absent in SuperVero cells. As expected, Vero cells do not contain
SV40-specific mRNAs (Table 1).
The 202 LTag-specific cDNA reads of SuperVero cells were aligned
and are homologous to the DNA sequence of pHY359 used to
generate the cell line. Sequence variants were not present among
the 202 sequenced cDNAs (Figure 3A).
The remaining cDNA reads obtained from the SuperVero cells with
the MP-Seq method were compared with a viral sequence database
(ViralDB) that contains 964,619 sequences extracted from the com-
plete GenBank nucleotide sequence database.40 The most significant
homologies found in the comparison are shown in Table 1. In the
SuperVero sample, cDNAs were found that show homology to human
herpesvirus 5 DNA. This homology corresponds with a short tran-
scribed region in the cytomegalovirus immediate early (CMVie) pro-
moter that drives transcription of the pac puromycin-resistance gene.
All other sequence homologies found between cDNAs from the
SuperVero cells and the ViralDB are also found when the cDNAs
from the Vero ATCCCCL-81 cells were compared with the sequences
in the database. The MP-Seq study has shown that the SuperVero cell
line is not contaminated with known viruses during its generation
from Vero ATCC CCL-81 cells.Molecular ThThe presence of the LTag protein in SuperVero cells was subsequently
confirmed by western blot analysis. Both LTag and STag proteins can
be detected using an antibody specific for the N-terminal part of the
LTag protein. As expected, COS-1 cells accumulate both LTag and
STag, whereas SuperVero cells express only LTag (Figure 3B). Immu-
nocytochemistry of the SuperVero and COS-1 cells further confirmed
the presence of the LTag in the nucleus of the cells (Figure 3C). A
densitometric analysis of the bands on the western blots revealed
that the relative amount of LTag in SuperVero cells was slightly lower
than that in COS-1 cells (Figure 3D).
The SV40 late gene encoding the capsid proteins is exclusively
expressed in cells permissive for SV40 that accumulate the viral
LTag. This implies that the viral capsid proteins are produced only
in the packaging cells during vector manufacturing, but absent in
(human) target cells after transduction. The transcriptional silencing
of the SV40 late gene in cells lacking the viral LTag was verified by
transfecting SuperVero and HeLa cells with pSVGFP DNA. After
3 days, the presence of GFP, LTag, and the major viral capsid protein
VP1 in both cell types was checked on western blots using mono-
clonal antibodies specific for GFP, LTag, and VP1, respectively. A
monoclonal antibody specific for GAPDH was included as a protein
loading control. Only SuperVero cells constitutively produce SV40
LTag. In both pSVGFP-transfected SuperVero and HeLa cells, GFP
was detected. However, VP1 accumulated only in pSVGFP-trans-
fected SuperVero cells, demonstrating that the SV40 late gene is not
expressed in target cells lacking SV40 LTag (Figure 4).
Production of SV40 Vector Particles in SuperVero Cells
When COS-1 cells cultured in medium with fetal bovine serum and
SuperVero cells cultured in serum-free medium are transduced
with SV40 vector particles at an MOI of 400 vector particles pererapy: Methods & Clinical Development Vol. 6 September 2017 127
Figure 3. SuperVero Cells Contain pHY359 DNA and Express SV40 LTag
(A) Schematic representation of the cDNA reads from the MP-seq analysis corre-
sponding with the SV40 LTag mRNA expressed in SuperVero cells. (B and C)
Detection of the LTag protein in SuperVero cells (B) by western blot and (C) by
immunocytochemistry using a mouse monoclonal antibody specific to the amino-
terminal region of the LTag and STag. Vero cells are used as a negative control.
COS-1 cells are used as a positive control expressing both LTag and STag. (D)
Densitometric analysis of the western blot bands shown in (B). The graph represents
the ratio between the density units of LTag and a-tubulin, used as an internal loading
control.
Figure 4. The SV40 Late Gene Is Only Expressed in SuperVero Cells during
the Production of Vector Particles and Not in Human Target Cells
Detection of GFP, SV40 LTag, and major capsid protein VP1 in cell lysates from
SuperVero and HeLa cells transfected with pSVGFP DNA by western blot analysis
using antibodies specific for GFP, LTag, and VP1. An anti-GAPDH antibody was
used as a loading control.
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128 Molecular Therapy: Methods & Clinical Development Vol. 6 Septemcell, both cell lines secreted comparable numbers of vector particles in
the culture medium (Figure 5A). The capacity of SuperVero cells to
produce consistent amounts of SV40 particles was further tested by
passaging vector particles in fresh SuperVero cells and measuring
the number of vector particles after each passage. In SuperVero cells
transduced with SVLuc particles obtained at subsequent passages,
consistently 108–109 vector particles per milliliter cell culture are
found in the cell culture medium (Figure 5B). Moreover, approxi-
mately the same numbers of vector particles remain inside the cells
and are not harvested after production (data not shown). The trans-
duction efficacy (potency) of the produced vector particles after each
passage was determined using a modified tissue culture infectious
dose 50 (TCID50) assay. Because SV40 vector particles do not lyse
transduced cells, we used SVLuc as a reporter vector and used lumi-
nescence as a readout in this limited dilution assay. These experi-
ments revealed that the vector particles quantified by qPCR (Fig-
ure 5B) remain fully functional after passaging them in SuperVero
cells as determined by TCID50 (Figure 5C). Furthermore, defective
interfering vector particles do not accumulate during the vector pro-
duction process as demonstrated by the stability of the TCID50 titer
over subsequent passaging (Figure 5C).
We next produced SVLuc, SVGFP, SVFVIIa, and SVshLuc vector
batches in SuperVero cells. The vector yields obtained after three pas-
sages consistently ranged between 108 and 109 particles per milliliter
cell culture, demonstrating the robustness of the vector production
process (Figure 5D).
SVLuc particles produced in SuperVero cells were stored for different
periods of time at different temperatures. The numbers of vector par-
ticles were determined by qPCR (Figure 6A), whereas the potency of
the particles was determined using the TCID50 assay (Figure 6B). In-
dependent of the storage temperature, the amounts of vector particles
did not significantly decrease after 6 months. These experimentsber 2017
Figure 5. SuperVero Cells Consistently Accumulate Large Amounts of
Functional SV40 Vector Particles
(A) Determination of the number of SVLuc particles produced in COS-1 and
SuperVero cells using qPCR. (B) Determination of the number of SVLuc particles
after passaging in SuperVero cells. (C) Determination of the potency of SVLuc
particles after passaging in SuperVero cells. (D) Determination of the number of
SV40 vector particles expressing different transgenes produced in SuperVero cells.
Error bars represent SD, n = 3.
Figure 6. SV40 Vector Particles Remain Functional after Storage for 6
Months at 4C or Lower Temperatures
SVLuc particles were stored at +4C,20C,80C, and150C. (A) The number
of vector particles was determined by qPCR. (B) The potency of the vector particles
was determined by the TCID50 analysis.
www.moleculartherapy.orgdemonstrate that SV40 vector particles stored at 4C or at lower tem-
peratures remain fully functional for at least 6 months.
Detection of RC SV40 Particles
It has been found that the production of SV40 vectors in COS cells
results in the emergence of RC SV40 particles.33 In order to sort
out whether the virus contamination problem is solved by using the
SuperVero cell line (Figure 7), we designed a set of primers to detect
RC SV40 particles by qPCR (Figure 8).
In all the samples tested so far using these primers, including samples
from highly concentrated vector preparations and samples from sub-
sequent vector passages (up to 10), the number of RC SV40 particles
remained below the detection limit of the assay. This means that after
passaging the vector particles in SuperVero cells, RC SV40 particles
certainly do not overgrow the RD vector particles.
DISCUSSION
SV40 gene delivery vectors have shown therapeutic efficacy in
numerous preclinical studies,22–25,41 and because of their predictedMolecular Thnon-immunogenic/tolerogenic potential in humans these vectors
are an attractive alternative to the currently used vector systems for
developing safe and efficient gene therapies. To date, however,
SV40 vectors have not been tested in clinical trials because an efficient
packaging cell line that does not accumulate RC SV40 particles during
the vector production process is lacking. Here we report on the devel-
opment of an SV40-based gene delivery platform, which we named
SVac, that is well suited for producing RD SV40 vector particles
free of contaminating RC revertants, and thus eligible for use in clin-
ical gene therapy studies.
We developed a versatile SV40 vector destination plasmid (pSVac)
that allows the evaluation of promoters, transgenes, and other regula-
tory elements for safety and efficacy in animals and humans. Vero
cells were selected for the generation of a new packaging cell line
because this cell line is permissive to SV40 and is recommended by
the World Health Organization for vaccine production for human
use.42
RD SV40 vector genomes lack the T antigen region. In order to pro-
duce SV40 vector particles, T antigen must be provided by the pack-
aging cell line. The SV40 early gene encodes LTag and STag. LTag is a
replicase-associated protein required for viral DNA replication and
for activation of the viral late promoter.43 STag inhibits cellular pro-
tein synthesis from capped messenger RNAs (a process denoted host
shutoff), thereby promoting the synthesis of viral capsid proteins.44
Simultaneous expression of LTag and STag results in immortalization
of primary mammalian cells, transformation of established mamma-
lian cell lines, and induction of tumors in immuno-compromised
young-born hamsters. However, it has been shown that expression
of the individual T antigens in mammalian cells does not lead to
immortalization, transformation, or tumor induction.45 We here
show for the first time that expression of the LTag in the absence of
STag in Vero cells is sufficient for the replication and packaging of
SV40 vector particles. A Vero-based SV40 packaging cell line
denoted SuperVero was generated that expresses the viral LTag,
and thus lacks the viral oncogene and oncoproteins. Because sequence
overlap between chromosomally inserted SV40 LTag coding se-
quences and episomally replicating SV40 vector sequences is lacking,erapy: Methods & Clinical Development Vol. 6 September 2017 129
Figure 7. Production of SV40 Vectors in SuperVero
and COS-1 Cells
The production of SV40 particles in COS-1 cells (right
side) results in the emergence of RC SV40 particles
because of homologous recombination between chro-
mosomal inserted SV40 sequences and episomally
replicating SV40 DNA sequences. The generation of RC
variants is prevented in SuperVero cells (left side)
harboring chromosomally inserted SV40 LTag DNA se-
quences without sequence overlap to the episomally
replicating SV40 vector DNA sequences.
Molecular Therapy: Methods & Clinical Developmentthe emergence of RC particles during the vector production process is
highly unlikely.
We demonstrate that the LTag in SuperVero cells activates transcrip-
tion from the viral late promoter, resulting in the accumulation of
capsid proteins during the vector production process. However, in
target cells lacking SV40 LTag transduced with an RD SV40 vector,
only the transgene is expressed from the viral early promoter.
From the previous attempts to generate an SV40 vector packaging cell
line it was found that the amount of the LTag is directly correlated
with the number of SV40 vector particles,33,34 but inversely correlated
with cell viability.33 This could be the reason why we had to screen
more than a hundred independent puromycin-resistant clones to
identify one cell clone that is capable of producing vector particles130 Molecular Therapy: Methods & Clinical Development Vol. 6 September 2017to levels comparable with those in COS cells.
Remarkably, this cell clone accumulates LTag
to levels similar to COS-1 cells. Apparently
there is a narrow margin of LTag expression
tolerated by Vero cells that supports SV40 vec-
tor replication. We initiated experiments to
further increase the amount of LTag in the
packaging cells during the production process
to even improve the vector yields.
The SV40 vector particles remain fully func-
tional after passaging them in SuperVero cells,
indicating that defective interfering particles
do not accumulate during the production pro-
cess. Furthermore, the produced vector particles
are highly stable upon storage at 4C or lower
temperatures. The major advantage of Super-
Vero packaging cells above COS cells for pro-
ducing RD SV40 vector particles is the absence
of contaminating RC SV40 particles during the
vector production process.32
The circular vector DNA molecules used in our
studies to start the production of SV40 vector
particles in SuperVero cells are similar, with
the same genetic elements, to those used in pre-
vious studies to produce vector particles inCOS cells. Because both Vero and CV1 cell lines are derived from
kidney tissue obtained from African green monkeys (Cercopithecus
aethiops),46 it is assumed that the in vivo transduction efficacy of
SV40 vector particles produced in a Vero-derived packaging cell
line is similar to that of particles produced in CV1-derived packaging
cell lines such as COS. Indeed, ongoing in vivo studies with SVGFP
and SVLuc particles produced in SuperVero cells show high transduc-
tion rates and transgene expression levels of different organs and/or
tissues depending on the mode of administration (unpublished data).
Overall, RD SV40 vectors are efficient, non-immunogenic/tolerogenic
in humans, highly stable, safe to use, and can be produced in large
quantities in SuperVero packaging cells. The generation of the SVac
platform described here paves the way for developing the next wave
of medicines. SV40 vectors expressing functional gene products can
Figure 8. Primers and Probes Used for the qPCR Analysis to Detect RC and
RD SV40 Vector Particles
(A) Schematic representation of the SV40 genome showing the position of the
primers and probe for the detection of RC SV40 particles. (B) The sequences of
primers and probes used in the qPCR analysis.
www.moleculartherapy.orgbe used in gene replacement therapies to treat genetic disorders such
as, for example, low-density lipoprotein receptor deficiency, primary
hyperoxaluria type 1, or hemophilia. In addition, SV40 vectors ex-
pressing T cell receptors (TCRs) or chimeric antigen receptors
(CARs) can be used as vaccines to treat cancer. Last but not least,
because of their capacity to induce immune tolerance to the transgene
products in humans, SV40 vectors expressing primary self-antigens of
degenerative/autoimmune diseases can be used as reverse vaccines to
treat the major diseases of our time, such as neurodegenerative and
psychiatric diseases,37 atherosclerotic cardiovascular disease, diabetes
mellitus, arthritis, and chronic obstructive pulmonary disease (COPD).MATERIALS AND METHODS
Plasmid Construction
Expression plasmid pHY338 was constructed using a pBluescript
SK (Stratagene; Agilent Technologies) backbone by adding a gene
cassette comprising the SV40 T antigen coding sequence (NCBI refer-
ence sequence NC_001669.1) flanked by the EF-1a promoter and the
BGH pA signal (EF-1a-T antigen-BGH pA) and a gene cassette
comprising the pac puromycin resistance gene flanked by the human
CMVie promoter and the BGH pA (CMVie-pac-BGH pA).
Expression plasmid pHY359 exclusively expressing the SV40 LTag
was generated by deletion of the large intron from the T antigen
coding sequence by fusion PCR from plasmid pHY338 as follows.
First, with forward primer 50-GCAGGCTACCATGGATAAAGTTT
TAAACAGAGAG-30 homologous to the 50 end of the LTag
coding sequence and reverse primer 50-CCCATTCATCAGTTCC
ATAGGTTGGAATCTCAGTTGCATCCCAGAAGCCTCCAAAG-30
covering the intron splice site, a first PCR fragment was generated
comprising the 50 end of the LTag sequence. Second, with forward
primer 50-CTTTGGAGGCTTCTGGGATGCAACTGAGATTCCA
ACCTATGGAACTGATGAATGGG-30 covering the intron splice
site and reverse primer 50-AGGAATGTTGTACACCATGCATTT
TAAAAAGTC-30 covering the NsiI site in the center of theMolecular ThLTag coding domain, a second PCR fragment was generated.
Third, the two PCR fragments were used to perform a fusion
PCR using the two external primers. The generated PCR fragment
comprising the 50 end of the LTag coding sequence without the
large intron was cloned into the NcoI-NsiI sites of expression
plasmid pHY338 yielding expression plasmid pHY359.
Cell Line Generation
Vero cells (ATTC, CCL-81) were cultured in serum-free OptiPRO
(GIBCO, Thermo Fisher Scientific) medium supplemented with
4 mM glutamine (GIBCO, Thermo Fisher Scientific). The pBluescript
SK backbone was removed from the pHY359 DNA, and Vero cells
were transfected with the DNA fragment containing the pac and
LTag gene cassettes using ExGen 500 in vitro Transfection Reagent
(BIOMOL) following the manufacturer’s instructions. Two days after
transfection, the cells were divided into culture medium containing
2 mg/mL puromycin (Sigma-Aldrich) and kept under the antibiotic
pressure for 1 month.
Construction of SV40 Destination Vector Plasmid pSVac
DNA of pSL-PL was subjected to PCR using primers 50-CGGGATC
CAGACATGATAAGATACATTG-30 and 50-ATAGTTTAGCGGC
CGCAATGAATGCAATTGTTGTTGTTAACTTG-30. The resulting
PCR fragment comprising the SV40-pA signal was cloned into
pBluescript SK yielding pAM002. Plasmid pEF5/FRT/5-DEST
(Invitrogen) DNA was subjected to PCR using primers 50-CCG
CTCGAGTTGCGGCCGCTGTGCCTTCTAGTTGCCAGCCATC-30
and 50-GGTACCATAGAGCCCACCGCATCCCCAGCATGCC-30.
The resulting PCR fragment comprising the BGH pA was




were annealed, digested withNotl and CIaI, and cloned into pAM003,
yielding pAM004. Plasmid pSL-PL DNA containing the SV40 origin
and late region was digested with CIaI and BamHI, and cloned into
pAM004, resulting in pAM005. Plasmid pEF5/FRT/5-DEST DNA
was subjected to PCR using primers 50-TGGCGCGCCTATAGGGA
GACCCAAGCTGGCTAG-30 and 50- CAATCATACCGTTTAAAC
GAACCGCGGGCCCTCTAGAC-30. The resulting PCR fragment
comprising the ccdB Gateway and the chloramphenicol resistance
(CmR) gene cassettes flanked by AttR1 and AttR2 recombination sites
was cloned into pAM005, resulting in SV40 destination vector
plasmid pSVac.
SV40 Vector Production
Vector batches were produced according to Vera et al.31 In brief, after
digestion of SV40 expression plasmid DNA with NotI to remove the
bacterial backbone, vector DNA was isolated from agarose gels and
subsequently re-circularized using T4 ligase (NEB). SuperVero cells
growing in roller bottles (growth area: 850 cm2; Greiner Bio One)
to 20%–70% confluence in OptiPRO serum-free media containing
4 mM L-glutamine (5% carbon dioxide, 37C) were transfected with
the re-circularized vector DNA. Three days posttransfection, theerapy: Methods & Clinical Development Vol. 6 September 2017 131
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placed by fresh medium. In order to further increase the number of
vector particles, we used the pooled vector harvests for at least two
subsequent transduction rounds. In each transduction round, Super-
Vero cells were transduced with 400 SV40 vector genomes per cell.
Three days posttransduction, the vector particle-containing culture
medium was collected and replaced by fresh media. Vector harvests
were clarified and concentrated by ultracentrifugation, and stored
at 4C or other temperatures as indicated.
SV40 Vector Quantification
The concentration of the vector particles in the produced vector
batches was determined by quantitative real-time PCR. Samples
were treated with DNase I (Sigma-Aldrich) to remove naked
DNA. The vector DNA was isolated from particles by incubating
the samples at 37C for 1 hr in a proteinase K (Sigma-Aldrich)
working solution (2.75 mg/mL in 8.6 mM Tris-HCl, 86 mM
NaCl, 0.43% w/v SDS, pH 8). Magnetic beads (MagneSil Blue;
Promega) were used to selectively bind vector DNA. Isolated
DNA was used as a template for amplification of the VP2 gene re-
gion using AmpliTaq Gold (Thermo Fisher Scientific) polymerase
and primers and probes shown in Figure 8B. The qPCR was set up
according to the manufacturer’s recommendations (7300 Real-
Time PCR System; Applied Biosystems) under the thermal cycling
conditions of 2 min at 50C and 10 min at 95C, proceeding with
40 cycles of denaturation at 95C for 15 s and annealing or exten-
sion at 60C for 1 min. Data analyses were performed on the
Applied Biosystems software.
The potency of SVLuc particles in the produced vector batches was
determined using a modified TCID50 assay. This limited dilution
assay quantifies the number of vector particles needed to transduce
50% of the target cells. In this assay, SVLuc particles were used as a
reporter vector, and luminescence was used as a readout. Ten-fold
serial dilutions of the SVLuc samples to be tested were added in
quadruplicates to a 96-well cell culture plate containing 2  103
SuperVero cells in 100 mL of serum-free OptiPRO medium. Cells
were exposed to the serial diluted vector and incubated in 5% carbon
dioxide and at 37C for 4 days. A dilution series of a standard SVLuc
batch was added to the plates as a control. Intracellular luciferase was
subsequently measured by luminescence. The estimated vector titer
is the endpoint dilution at which 50% of the cell cultures (wells)
are transduced by SVLuc and show luciferase expression. Vector
titers were calculated according to the Spearman-Karber method
and expressed as TCID50 per milliliter SuperVero cell culture
(TCID50/mL).
Detection of RC SV40 Particles
The absence of RC SV40 revertants in the produced SV40 vector
batches was confirmed by qPCR. Vector DNA was isolated from
vector preparations using the PureLink RNA/DNA Mini Kit
(Invitrogen). Isolated DNA was used as a template to amplify a frag-
ment of 108 bp comprising the SV40 pA sequence and LTag coding
region using the primers and probes shown in Figure 8. Plasmid132 Molecular Therapy: Methods & Clinical Development Vol. 6 SeptempAM271 DNA harboring the wild-type SV40 genome was used as a
positive control. The qPCR was set up according to the manufacturer
(7300 Real-Time PCR System; Applied Biosystems) under the
thermal cycling conditions of 2 min at 50C and 10 min at 95C, pro-
ceeding with 40 cycles of denaturation at 95C for 15 s and annealing
or extension at 60C for 1 min. Data analyses were performed on the
Applied Biosystems. Based on the signal obtained with the non-tem-
plate control samples, we defined the limit of detection of the assay to
be 60 RC SV40 particles per milliliter.
Luciferase Activity Measurements
Luciferase activity wasmeasured from cells transduced with SVLuc by
using the Luciferase Assay System (Promega). 200 mL of vector stock
was used to transduce 1 104 cells in a 24-well plate format. All trans-
ductions were performed in triplicate. Three days after transduction,
cells were harvested and luciferase activity was analyzed in a GloMax
96 Microplate Luminometer (Promega) according to the manufac-
turer’s recommendations.
Western Blot Analysis
Cells were lysed with SAM buffer (50 mM Tris-HCl, pH 6.8, 3% of
SDS, 5% of b-mercapto-ethanol) containing protease inhibitor
cocktail (SIGMAFAST Protease Inhibitor Tablets; Sigma-Aldrich),
resolved by SDS-PAGE (10% polyacrylamide gels under reducing
conditions) and electro-transferred to nitrocellulose membranes
(Bio-Rad Laboratories). Membranes were blocked with 5% nonfat
milk and probed with different primary antibodies for 1 hr at room
temperature: (1) mouse anti-SV40 LTag 0.5 mg/mL (BD Biosci-
ences), dilution 1:200; (2) rabbit anti-VP1 (Abcam), dilution
1:5,000; (2) mouse anti-GFP (Sigma-Aldrich), dilution 1:1,000;
mouse anti-a-tubulin antibody (Sigma-Aldrich), dilution 1:5,000;
mouse anti-GAPDH (Millipore), dilution 1:5,000. Finally, the
membrane was hybridized with a goat anti-mouse or a goat anti-
rabbit antibody conjugated with horseradish peroxidase (HRP)
(Sigma-Aldrich), dilution 1:5,000. The blot was developed by
chemiluminescence (Chemidoc MP Imaging System; Bio-Rad Lab-
oratories). To quantify the amounts of protein, we scanned the
blots by densitometry using the Image Lab software version 5.2.1
(Bio-Rad Laboratories).
Immunocytochemistry
SuperVero, Vero ATCC CCL-81, and COS-1 cells were cultured on
coverslips and were fixed with 4% paraformaldehyde and blocked
with 2% bovine serum albumin for 1 hr at room temperature. We
incubated the cells overnight at 4C with a solution of 2.5 mg/mL
mouse antibody to the SV40 LTag diluted in PBS, 0.2% of Triton
X-100. The secondary antibody (Alexa Fluor 488 donkey anti-goat;
Life Technologies, Invitrogen) was incubated for 1 hr at room tem-
perature diluted at 1:800 in PBS, 0.2% Triton X-100. Nuclear staining
was performed with a solution of 5 mg/mL DAPI (Life Technologies,
Invitrogen), and the slides were finally mounted using fluorescent
mounting medium (DAKO, Agilent Technologies). Fluorescence
microscopy images were acquired using a Leica DM6000B micro-
scope (Leica Microsystem).ber 2017
www.moleculartherapy.orgStatistical Analysis
All experiments were performed with a minimum of n = 3. All the sta-
tistical analyses were performed with the GraphPad Prism 5 software.
We applied the two-tailed unpaired Student t test.
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